Ralph A. Tripp

University of Georgia

H指数:73

被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Label-free surface-enhanced Raman spectroscopy and machine learning for rapid classification and quantification of bovine respiratory disease complex viruses

基于无标记表面增强拉曼光谱和机器学习的牛呼吸道疾病复合病毒快速分类与定量

Talanta

IF6.1

2026-07-010

PRE

RSV nucleoprotein inhibitors in preclinical to phase II clinical development for respiratory syncytial virus infection

RSV核蛋白抑制剂在针对呼吸道合胞病毒感染的从临床前到II期临床的开发中

Expert Opinion on Investigational Drugs

IF4.1

2026-02-240

Intersection of inflammation and viral replication: the central role of MAPK signaling in viral respiratory infections

Frontiers in Microbiology

IF4.5

2026-01-240

OAAI

Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells

评估Probenecid对Filovirus在Vero E6细胞中复制的影响

Viruses 2026, Vol. 18, Page 43

IF3.5

2025-12-270

OAAI

Probenecid Treatment Inhibits Replication of the Edmonston Measles Virus Strain in Vero Cells

丙磺舒处理抑制Edmonston麻疹病毒株在Vero细胞中的复制

VIRUSES-BASEL

IF3.5

2025-11-050

OAAI

Restricting O-Linked Glycosylation of the Mucin-like Domains Enhances Immunogenicity and Protective Efficacy of a Respiratory Syncytial Virus G Glycoprotein Vaccine Antigen

限制黏液素样结构域的O-连接糖基化可增强呼吸道合胞病毒G糖蛋白疫苗抗原的免疫原性和保护效力

Vaccines 2025, Vol. 13, Page 1004

IF3.4

2025-09-290

OAAI

Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs)

Probenecid 抑制 NLRP3 炎症小体活性以及丝裂原活化蛋白激酶（MAPKs）。

BIOMOLECULES

IF4.8

2025-04-011

Evaluating Probenecid or Oseltamivir Inhibition of Influenza A Virus Replication Through Plaque Assay or Fluorescent Focus Assay Using Non-Structural Protein 1-H1N1 Venus Reporter Virus

VIRUSES-BASEL

IF3.5

2025-02-270

OAAI

Multiplex Detection and Quantification of Virus Co-Infections Using Label-free Surface-Enhanced Raman Spectroscopy and Deep Learning Algorithms

使用无标记表面增强拉曼光谱和深度学习算法对病毒共感染进行多重检测和定量

ACS SENSORS

IF9.1

2025-01-280

Editorial: How RSV outsmarts the host

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-12-200

OAAI

Antiviral agents and therapeutics against respiratory viruses

EXPERT OPINION ON INVESTIGATIONAL DRUGS

IF4.1

2024-09-081

PRE

Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice

VIRUSES-BASEL

IF3.5

2024-07-061

OAAI

Advancing SERS Diagnostics in COVID-19 with Rapid, Accurate, and Label-Free Viral Load Monitoring in Clinical Specimens via SFNet Enhancement

通过SFNet增强功能在临床标本中进行快速，准确和无标记的病毒载量监测，从而在新型冠状病毒肺炎中推进SERS诊断

ADVANCED MATERIALS INTERFACES

IF4.4

2024-03-312

Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice

丙磺舒在体外和小鼠体内抑制甲型 (H5N1) 和甲型 (H7N9) 流感病毒

VIRUSES-BASEL

IF3.5

2024-01-194

OAAI

Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication

VIRUSES-BASEL

IF3.5

2023-11-307

OAAI

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

筛选具有广谱，宿主导向的抗病毒活性的药物: 开发丙磺舒用于新型冠状病毒肺炎的经验教训

VIRUSES-BASEL

IF3.5

2023-11-147

OAAI

Understanding immunity to influenza: implications for future vaccine development

EXPERT REVIEW OF VACCINES

IF4.8

2023-10-125

Interferons-Implications in the Immune Response to Respiratory Viruses

MICROORGANISMS

IF4.2

2023-08-298

OAAI

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

VIRUSES-BASEL

IF3.5

2023-07-067

OAAI

Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-06-291

OAAI

Ralph A. Tripp

个人简介

教育背景

工作经历

荣誉奖项

研究方向